A randomized equivalence trial comparing the efficacy and safety of Luffa comp.-Heel nasal spray with cromolyn sodium spray in the treatment of seasonal allergic rhinitis.
BACKGROUND
The objective of the clinical study was to investigate the efficacy and tolerance of a homeopathic nasal spray in cases of hay fever (seasonal allergic rhinitis) in comparison with the conventional intranasal cromolyn sodium therapy.


METHODS
In total, 146 outpatients with symptoms of hay fever were enrolled into the clinical study (randomized, double-blind, equivalence trial) (time of treatment: 42 days). The homeopathic remedy (Luffa comp.-Heel trade mark Nasal Spray, dosage: 0.14 ml per application, 4 times per a day / naris) consisted of a fixed combination made up of Luffa operculata, Galphimia glauca, histamine, and sulfur. The main outcome measure of the efficacy was the quality of life as measured by means of the Rhinoconjunctivitis Quality of Life-Questionnaire (RQLQ). The tolerance of the trial medication was registered by means of global assessment, rhinoscopy, recording of adverse events and with the aid of vital and laboratory parameters.


RESULTS
The results of the study demonstrate a quick and lasting effect of the treatment. This effect was independent from the medication applied and produced a nearly complete remission of the hay fever symptoms. The RQLQ global score changed significantly in the course of the treatment, indicating therapeutic equivalence between the two forms of treatment. Adverse systemic effects did not occur. Local adverse events appeared in 3 patients.


CONCLUSIONS
The study proved that, for the treatment of hay fever, the homeopathic nasal spray is as efficient and well tolerable as the conventional therapy with cromolyn sodium.
Weiser
M
M
Institut für Antihomotoxische Medizin und Grundregulationsforschung, Baden-Baden, Mannheim, Germany.
Gegenheimer
L H
LH
Klein
P
P
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D000485:Allergens; D018927:Anti-Asthmatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004205:Cromolyn Sodium / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006632:Histamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006705:Homeopathy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010936:Plant Extracts / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000628:therapy*; D013455:Sulfur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013810:Therapeutic Equivalency
D000485:Allergens; D018927:Anti-Asthmatic Agents; D010936:Plant Extracts; D013455:Sulfur; D006632:Histamine; D004205:Cromolyn Sodium